BeyondSpring Inc.

115 articles with BeyondSpring Inc.

• BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update

  6/16/2021

  BeyondSpring today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent corporate events.

• 

  Clinical Catch-Up: June 7-11

  6/14/2021

  A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.

• BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

  6/11/2021

  BeyondSpring Inc. today announced that management will host a conference call to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate events on June 16, 2021 at 8:30 AM Eastern Time.

• BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

  6/10/2021

  BeyondSpring Inc. announced presentation of data from the PROTECTIVE-1 Phase 3 clinical study of plinabulin for prevention of chemotherapy-induced neutropenia at the American Society of Clinical Oncology Annual Meeting being held on June 4 - 8, 2021.

• BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the ASCO Annual Meeting

  6/7/2021

  Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone

• BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

  6/4/2021

  Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy

• BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

  6/1/2021

  Plinabulin and G-CSF combination has the potential to raise the standard of care in CIN prevention for the first time in 30 years

• BeyondSpring to Present at the Bank of America Securities 2021 Health Care Conference on May 13, 2021

  5/10/2021

  BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that that CEO Dr. Lan Huang is scheduled to present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 8:00 am ET and will be available for 1x1 meetings.

• BeyondSpring Files 2020 Annual Report on Form 20-F

  4/30/2021

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission on April 30, 2021.

• BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update

  4/30/2021

  - NDAs filed in the U.S. and China in Mar. 2021 based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention of CIN - Company subsidiary, SEED Therapeutics, signed an $800 million research collaboration with Eli Lilly leveraging its proprietary targeted protein degradation (TPD) platform in Nov. 2020 - Completed $86.3 million equity financing in Nov. 2020. Cash and cash equivalents of $109

• BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

  4/28/2021

  BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced five presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually June 4-8, 2021.

• BeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021

  4/27/2021

  BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter and year ended December 31, 2020 on Friday, April 30, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time.

• BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

  4/1/2021

  Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone

• BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

  3/11/2021

  BeyondSpring, a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it will host a key opinion leader webinar on Plinabulin, the Company’s lead asset for the prevention of chemotherapy-induced neutropenia on Thursday, March 18, 2021 at 10:00 a.m. Eastern Time.

• BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

  12/29/2020

  BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the 39 th Annual J.P. Morgan Healthcare Conference (JPM) on Thursday, January 14, 2021 at 7:30 a.m. ET, and will be available for 1x1 meetings. The BeyondSpring leadership team also will be available for one-on-one meeti

• 

  BioSpace Movers & Shakers, Dec. 18

  12/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

  12/17/2020

  BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherap

• BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference

  11/23/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020.

• BeyondSpring Announces Pricing of Ordinary Shares - Nov 19, 2020

  11/19/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the pricing of its public offering of 7,500,000 ordinary shares at a public offering price of $10.00 per share.

• BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates

  11/17/2020

  BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results and provided an operational update for the three months ended September 30, 2020. “ We were thrilled to announce positive top-line data in our pivotal Ph